 |
N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl(phenyl]amino}pyrimidin-4-yl)benzamide |
|---|---|
| Trade Name | |
| Orphan Indication | Myelofibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2010-08-05 00:00:00 |
| Sponsor | Gilead Sciences, Inc.;333 Lakeside Drive;Foster City, California, 94404 |
Related Access Program